JCR Pharmaceuticals (JCRRF) News Today $4.57 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartHeadlinesShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period JCR Pharmaceuticals Faces Financial Decline Amid Strategic ChangesNovember 18 at 1:00 AM | tipranks.comJCR Pharmaceuticals Completes Share Buyback for Strategic GrowthNovember 1, 2024 | markets.businessinsider.comJCR Pharmaceuticals Initiates First Dosing in Phase I Clinical Trial of JR-441 for Mucopolysaccharidosis Type IIIAOctober 31, 2024 | businesswire.comJCR Pharmaceuticals Presents Preclinical Gene Therapy Research at the European Society of Gene and Cell Therapy 31st Annual CongressOctober 23, 2024 | businesswire.comJCR Pharmaceuticals Advances Gene Therapy ResearchOctober 23, 2024 | markets.businessinsider.comMesoblast: Undervalued Due To Remestemcel-L's Substantial Growth PotentialSeptember 30, 2024 | seekingalpha.comJCR Pharmaceuticals Highlights Innovative Gene Therapy Research at the 7th International Forum of Lysosomal DisordersJuly 19, 2024 | businesswire.comModalis Therapeutics Corporation (4883.T)May 25, 2024 | finance.yahoo.comJCR Pharmaceuticals Announces Achievement of Milestone Using J-Brain Cargo® Technology for Neurodegenerative Disease in Research Collaboration with AlexionMarch 19, 2024 | finance.yahoo.comJCR Pharmaceuticals Co Ltd 4552March 2, 2024 | morningstar.comJCR Pharmaceuticals Celebrates Rare Disease Day 2024 and Highlights Its Commitment to the Rare Disease CommunityFebruary 29, 2024 | finance.yahoo.comJCR Pharmaceuticals’ Research Presentations at WORLDSymposium™ 2024 Showcase JR-141 (Pabinafusp Alfa) and Other Investigational Treatments for Lysosomal Storage DisordersFebruary 14, 2024 | finance.yahoo.comJCR Pharmaceuticals earnings preview: what Wall Street is expectingJanuary 25, 2024 | markets.businessinsider.comJCR Pharmaceuticals to Present at the 20th Annual WORLDSymposium™ 2024January 25, 2024 | finance.yahoo.comJCR Announces Research Collaboration, Option and License Agreement with Alexion on Discovery of Oligonucleotide Therapeutics Using J-Brain Cargo® TechnologyDecember 21, 2023 | finance.yahoo.comJCR Pharmaceuticals and Takeda Pharmaceuticals Announce Discontinuation of Gene Therapy CollaborationDecember 21, 2023 | finance.yahoo.comU.S. FDA Grants Orphan Drug Designation to JR-441 for the Treatment of Mucopolysaccharidosis Type IIIA (MPS IIIA)December 15, 2023 | finance.yahoo.comJCR Pharmaceuticals doses first patient in MPS IIIA trialNovember 13, 2023 | msn.comJCR Pharmaceuticals earnings preview: what to expectOctober 24, 2023 | markets.businessinsider.comJCR Pharmaceuticals Announces 52-Week Interim Data from its Global Phase I/II Study of JR-171 in Individuals with Mucopolysaccharidosis Type I (MPS I)September 29, 2023 | finance.yahoo.comJCR Pharmaceuticals Shares Jump After It Raises Earnings GuidanceSeptember 28, 2023 | marketwatch.comHere's what Wall Street expects from JCR Pharmaceuticals's earnings reportJuly 27, 2023 | markets.businessinsider.comJCR Pharmaceuticals Co Ltd (4552)May 17, 2023 | investing.comItaly's Angelini invests up to $506 million in Japan's JCR for epilepsy drugMay 11, 2023 | news.yahoo.comItaly's Angelini invests up to $506 mln in Japan's JCR for epilepsy drugMay 11, 2023 | reuters.comJCR Pharmaceuticals Announces Research Collaboration, Option and License Agreement with Alexion to Develop a Therapy Using J-Brain CargoⓇ for Neurodegenerative DiseaseApril 3, 2023 | finance.yahoo.com Get JCR Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for JCRRF and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics… Get Your Free Gold Guide JCRRF Media Mentions By Week JCRRF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. JCRRF News Sentiment▼0.490.45▲Average Medical News Sentiment JCRRF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. JCRRF Articles This Week▼10▲JCRRF Articles Average Week Get JCR Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for JCRRF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AZNCF News DSNKY News KYKOF News MAYNF News OPHLY News OTSKF News RHHVF News SNYNF News VRBCF News TGIFF News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:JCRRF) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding JCR Pharmaceuticals Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share JCR Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy JCRRF with Qtrade Free JCRRF Stock Alerts